Rituximab effective in first-line CLL

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 2
Volume 17
Issue 2

In a pivotal phase III study, rituximab (Rituxan) in combination with standard chemotherapy significantly increased time to progression in patients with previously untreated chronic lymphocytic leukemia

BASEL, Switzerland—In a pivotal phase III study, rituximab (Rituxan) in combination with standard chemotherapy significantly increased time to progression in patients with previously untreated chronic lymphocytic leukemia, compared with chemotherapy alone.

In a press release, Roche, which markets the agent in Europe as MabThera, announced that the CLL8 trial, initiated by the German CLL study group, had reached its primary endpoint almost a year ahead of schedule.

The randomized international trial was conducted at 203 sites across 11 countries. It included 817 patients with CLL receiving first-line treatment—either rituximab with fludarabine and cyclophosphamide or chemotherapy alone. The study aimed to show a 35% increase in progression-free survival with rituximab.

Data from the CLL8 study will be submitted for presentation at upcoming international scientific meetings, the company said.

Recent Videos
Experts from Vanderbilt University Medical Center emphasize gathering a second opinion to determine if a tumor is resectable in patients with pancreatic cancer.
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Experts from Vanderbilt University Medical Center discuss the use of intraoperative radiation therapy in a 64-year-old patient with pancreatic cancer.
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Related Content